RadBone: bone toxicity following pelvic radiotherapy – a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy

Author:

Chatzimavridou Grigoriadou VictoriaORCID,Barraclough Lisa H,Baricevic-Jones Ivona,Bristow Robert G,Eden Martin,Haslett Kate,Johnson Karen,Kochhar Rohit,Merchant Zoe,Moore John,O’Connell Sarah,Taylor Sally,Westwood Thomas,Whetton Anthony David,Yorke Janelle,Higham Claire E

Abstract

IntroductionPatients receiving radiotherapy are at risk of developing radiotherapy-related insufficiency fractures, which are associated with increased morbidity and pose a significant burden to patients’ quality of life and to the health system. Therefore, effective preventive techniques are urgently required. The RadBone randomised controlled trial (RCT) aims to determine the feasibility and acceptability of a musculoskeletal health package (MHP) intervention in women undergoing pelvic radiotherapy for gynaecological malignancies and to preliminary explore clinical effectiveness of the intervention.Methods and analysisThe RadBone RCT will evaluate the addition to standard care of an MHP consisting of a physical assessment of the musculoskeletal health, a 3-month prehabilitation personalised exercise package, as well as an evaluation of the fracture risk and if required the prescription of appropriate bone treatment including calcium, vitamin D and—for high-risk individuals—bisphosphonates. Forty participants will be randomised in each group (MHP or observation) and will be followed for 18 months. The primary outcome of this RCT will be feasibility, including the eligibility, screening and recruitment rate, intervention fidelity and attrition rates; acceptability and health economics. Clinical effectiveness and bone turnover markers will be evaluated as secondary outcomes.Ethics and disseminationThis study has been approved by the Greater Manchester East Research Ethics Committee (Reference: 20/NW/0410, November 2020). The results will be published in peer-reviewed journals, will be presented in national and international conferences and will be communicated to relevant stakeholders. Moreover, a plain English report will be shared with the study participants, patients’ organisations and media.Trial registration numberNCT04555317.

Funder

MRC-NIHR Clinical Academic Research Partnership

MRC/EPSRC Molecular Pathology Node

Medical Research Council

Publisher

BMJ

Subject

General Medicine

Reference18 articles.

1. Macmillan Cancer Support . Statistics fact sheet. Available: https://www.macmillan.org.uk/_images/cancer-statistics-factsheet_tcm9-260514.pdf [Accessed Feb 2022].

2. Bone health and pelvic radiotherapy;Higham;Clin Oncol,2015

3. Pelvic insufficiency fractures after external beam radiation therapy for gynecologic cancers: a meta-analysis and meta-regression of 3929 patients;Sapienza;Int J Radiat Oncol Biol Phys,2020

4. Long-Term endocrine and metabolic consequences of cancer treatment: a systematic review;Gebauer;Endocr Rev,2019

5. Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults;van den Blink;Cochrane Database Syst Rev,2018

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3